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Abstract Bacterial lipopolysaccharide (LPS) in the presence of
interferon gamma (IFNQ) stimulates the synthesis of the cationic
amino acid transporter 2B (CAT-2B) and inducible nitric oxide
synthetase (iNOS) in RAW264 macrophages, which are thought
to underlie the increased rate of arginine uptake into these
cells and its conversion to nitric oxide, respectively. Here I
demonstrate that the LPS- and IFNQ-induced increase in
arginine uptake into RAW264 cells is partially suppressed in
the presence of PD 98059, partially suppressed in the presence of
SB 203580, and completely inhibited by both drugs. In contrast,
the LPS- and IFNQ-induced synthesis of CAT-2B mRNA and
iNOS protein is unaffected by PD 98059 and SB 203580. The
results indicate that the MAPK/ERK and SAPK2/p38 cascades
are both rate-limiting for LPS- and IFNQ-stimulated arginine
uptake, but not for iNOS synthesis. They also suggest that PD
98059 and SB 203580 suppress CAT-2B synthesis at a post-
transcriptional level.
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1. Introduction
Nitric oxide (NO) is an important mediator of signal trans-
duction in a variety of physiological systems (reviewed in [1]).
However, during bacterial infection, NO is generated in par-
ticularly large amounts by monocytes, macrophages and other
cells of the immune system. In these situations it is thought to
be cytostatic/cytotoxic for invading bacteria, although it may
also play other roles in regulating the release of interleukin-1,
a proin£ammatory mediator that is also produced by macro-
phages and monocytes during infection [2].
Nitric oxide is produced from arginine by nitric oxide syn-
thetase (NOS) and three NOS isoforms are found in mam-
malian cells. Type I NOS and type III NOS are calcium-
dependent enzymes that are expressed in a cell-speci¢c manner
and their activation produces the NO that mediates most of
the messenger functions of this molecule. In contrast, type II
NOS has a ubiquitous tissue distribution and is only expressed
during cell-mediated immune responses. For this reason it is
usually referred to as inducible NOS (iNOS) (reviewed in
[3,4]).
During bacterial infection, the lipopolysaccharide (LPS)
component of the bacterial cell wall interacts with the CD14
receptor in the plasma membranes of monocytes and macro-
phages [5] and activates signal transduction pathways that
trigger the synthesis of the iNOS protein and ensuing produc-
tion of NO. However, the formation of NO in vivo depends
not only on the activity of iNOS, but also on the availability
of its substrate arginine. Arginine is taken up into cells by
cationic amino acid transporter (CAT) systems in the plasma
membrane that also catalyse the transport of lysine and orni-
thine (reviewed in [6]). Three such transporters have been
identi¢ed termed CAT-1, CAT-2A and CAT-2B. CAT-1 and
CAT-2B are the species present in macrophages and mono-
cytes. In RAW264 macrophages, CAT-1 is expressed in the
absence of LPS and presumably accounts for the basal rate of
arginine uptake, while the LPS-induced production of CAT-
2B may underlie the increased rate of arginine uptake ob-
served under these conditions. Like the LPS-induced produc-
tion of iNOS, the LPS-induced synthesis of CAT-2B is greatly
stimulated if interferon gamma (IFNQ) is also present in the
culture medium.
The importance of CAT transporters and arginine uptake
for the production of NO is well documented. For example,
LPS/IFNQ-induced NO production does not occur in J774
macrophages (despite the induction of iNOS) if arginine is
excluded from the culture medium or in the presence of lysine
(which inhibits CAT-dependent arginine uptake by a compet-
itive mechanism) [7]. Similarly, NO production is only sus-
tained in brain cells if arginine is present in the extracellular
cerebrospinal £uid [8^10]. In cardiac endothelial (CMEC)
cells, glucocorticoids almost completely suppress LPS/IFNQ-
stimulated NO production, even though the synthesis of iNOS
declines by only 20% [11]. The e¡ect of glucocorticoids in
these cells appears to be mediated (at least in part) by inhib-
ition of CAT-1 and CAT-2B synthesis, resulting in suppres-
sion of arginine uptake.
The signal transduction pathways that trigger the induction
of iNOS and CAT-2B in macrophages (or any cell) have not
yet been identi¢ed. In this paper, we have addressed this ques-
tion by studying the e¡ects of two drugs, PD 98059 and SB
203580, that are speci¢c inhibitors of particular protein kinase
cascades. PD 98059 prevents the activation of MAP kinase
kinase-1 [12], the enzyme that activates the MAP kinase fam-
ily members MAPK1/ERK1 and MAPK2/ERK2 in the ‘clas-
sical’ MAP kinase cascade, while SB 203580 inhibits the MAP
kinase family members SAPK2a/p38 and SAPK2b/p38L2 [13]
which are components of a distinct protein kinase cascade
(reviewed in [14]). Here I show that LPS/IFNQ-stimulated ar-
ginine uptake is completely suppressed in the presence of both
PD 98059 and SB 203580, whereas the LPS/IFNQ-stimulated
induction of iNOS is una¡ected by these drugs.
2. Materials and methods
2.1. Materials
LPS was a generous gift from Dr. John Lee (SmithKline Beecham,
PA, USA), IFNQ, TRizol reagent and reagents for cell culture were
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purchased from Life Technologies (Paisley, UK), PD 98059 and SB
203580 from Calbiochem (Nottingham, UK) and a⁄nity-puri¢ed pol-
yclonal rabbit anti-iNOS antibody from Transduction Laboratories
(Lexington, KY, USA). Antibiotics, anisomycin, L-NG-monomethyl-
arginine (NMMA), L-lysine, L-arginine and the Griess reagent were
obtained from Sigma (Poole, UK), L-[2,3,4,5-3H]arginine hydrochlo-
ride from Amersham International (Bucks, UK) and the Access RT-
PCR System from Promega (Southampton, UK).
2.2. Cell culture, stimulation and cell lysis
A murine macrophage cell line, RAW 264 (European Cell Culture
Collection, Wilts, UK) was maintained in a 95% air/5% CO2 atmos-
phere in Dulbecco’s modi¢ed Eagle’s medium (DMEM) plus 10% (v/
v) heat-inactivated foetal calf serum, 100 U/ml penicillin, 100 Wg/ml
streptomycin and 250 ng/ml amphotericin B. For measurements of
iNOS and protein kinase activities, the macrophages were plated at
a density of 2U106 cells per 6-cm plate, the day before stimulation.
For measurements of arginine uptake, the macrophages were added to
24-well plates at a density of 2U105 cells per well. Two hours before
stimulation, the medium was removed and replaced with 2 ml of
DMEM. The cells were then stimulated with LPS (100 ng/ml) plus
IFNQ (10 U/ml). Where indicated, SB 203580 (10 WM) or PD 98059
(50 WM) were added 1 h before the stimulation.
After stimulation, the medium was collected, immediately snap-fro-
zen in liquid nitrogen and stored at 380‡C. These samples were used
to analyse nitrite production. The cells were then solubilised in 200 Wl
of ice-cold lysis bu¡er (50 mM Tris-acetate pH 7.0, 1 mM EDTA,
1 mM EGTA, 1% (w/v) Triton X-100, 1 mM sodium orthovanadate,
10 mM sodium glycerophosphate, 50 mM NaF, 5 mM sodium pyro-
phosphate, 0.27 M sucrose, 2 WM microcystin, 1 mM benzamidine,
0.2 mM phenymethylsulphonyl £uoride, 5 Wg/ml leupeptin, 0.1% (v/v)
2-mercaptoethanol). Lysates were centrifuged for 5 min at 13 000Ug
and the supernatants removed. After measurement of the protein
concentration [15], the samples were quick-frozen in liquid nitrogen
and stored in aliquots at 380‡C until analysis.
2.3. Immunoprecipitation and assay of protein kinases
MAP kinase-activated protein kinase-1 (MAPKAP-K1, also known
as RSK) was immunoprecipitated from cell lysates (50 Wg protein)
with an antibody raised against the peptide RNQSPVLEPVGRS-
TLAQRRGIKK corresponding to residues 605^627 of the murine
MAPKAP-K1b (RSK2) isoform. This antibody immunoprecipitates
MAPKAP-K1a (RSK1) as well as MAPKAP-K1b [12]. The immuno-
precipitates were washed and assayed at 30‡C as described [12]. One
unit of MAPKAP-K1 activity was de¢ned as that amount which
catalyses the incorporation of 1 nmol of phosphate into the peptide
[G245,G246]S6-(218^249) in 1 min. MAPKAP-K2 was immunopre-
cipitated in an identical manner using an antibody raised against the
peptide MTSALATMRVDYEQIK corresponding to residues 356^
371 of the human protein. This antibody immunoprecipitates MAP-
KAP-K3 as well as MAPKAP-K2. MAPKAP-K2 was assayed as
described [13] and one unit was that amount of enzyme which cata-
lyses the incorporation of 1 nmol of phosphate into the peptide
KKLNRTLSVA in 1 min.
2.4. Assay for nitrite
Frozen cell culture medium was thawed, centrifuged for 5 min at
13 000Ug to remove cellular debris, and the nitrite content of the
supernatant used to measure NO production. The supernatant was
incubated with the Griess reagent and the concentration of the result-
ing chromatophore determined spectrophotometrically at 540 nm [11].
The amount of nitrite was calculated by comparison with standard
sodium nitrite solutions.
2.5. Assay for L-arginine uptake
Cells were stimulated for the times indicated in the ¢gure legends.
The medium was then removed and the cells washed with 1 ml of
Dulbecco’s phosphate-bu¡ered saline (pH 7.4) comprising 0.9 mM
CaCl2, 0.5 mM MgCl2, 2.7 mM KCl, 1.5 mM KH2PO4, 137 mM
NaCl, 8.1 mM Na2HPO4 plus 0.1% (w/v) glucose. Cells were then
incubated for 10 min at 37‡C in 200 Wl of the same medium contain-
ing L-[3H]arginine (100 WM, 50.4 Ci/mmol; Amersham). In selected
experiments, 10 mM L-lysine was also present. Incubations were ter-
minated by immediately washing the cells three times with 1 ml ice-
cold Dulbecco’s phosphate-bu¡ered saline containing 10 mM unla-
belled L-arginine. Cells were solubilised in 0.5% (w/v) Nonidet P-40
and 0.1% (w/v) SDS and the radioactivity in the extract was quanti¢ed
by liquid scintillation counting [16].
2.6. Reverse transcriptase polymerase chain reactions
Total RNA was prepared from RAW264 cells using the TRizol
reagent according to the manufacturer’s protocol. Total RNA
was reverse-transcribed using Promega AMV reverse transcriptase
(5 U/ml) with the speci¢c antisense oligonucleotides CCAGAAA-
CAACCTAATCTGGTATA and TGTCACCAGCATCGAGAGGA
(for MCAT-1) and TTGTGTTACGAGCAGCCCAA and AGAAT-
GACGGCAGCGCAGAG (for MCAT-2B). Conditions for PCR am-
pli¢cation of the resulting ¢rst-strand DNA template were 94‡C de-
naturing, 60‡C annealing, 68‡C extension, 30 cycles using
thermostable T£ DNA polymerase (5 U/ml), and 1 mM MgSO4.
The PCR products of MCAT-1 (329 bp) and MCAT-2B (314 bp)
were subcloned into pCR-2.1 Topovector (Invitrogen) and the sequen-
ces con¢rmed using an applied Biosystems model 373A DNA se-
quencer.
3. Results
3.1. Stimulation of the MAPK/ERK cascades and the
SAPK2/p38 pathway by LPS in RAW264 macrophages
In order to examine the e¡ect of LPS on the MAPK/ERK
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Fig. 1. Activation of MAPKAP-K1 and MAPKAP-K2 by LPS in RAW264 macrophages. Macrophages were incubated for 1 h in the presence
(open circles) or absence (closed circles) of 50 WM PD 98059 (A) or 10 WM SB 203580 (B), then stimulated for the times indicated with LPS
(100 ng/ml) plus IFNQ (10 U/ml) in the continued presence or absence of the inhibitors. MAPKAP-K1 activity (A) or MAPKAP-K2 activity
(B) was then measured after immunoprecipitation from the lysates. The results are presented as means þ S.E.M. for two determinations from
two separate dishes. Similar results were obtained in three further experiments.
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and SAPK2/p38 cascades we studied the ability of this endo-
toxin to activate MAPKAP-K1 (a downstream target of
MAPK/ERK) and MAPKAP-K2 (a physiological substrate
for SAPK2/p38) (reviewed in [14]). LPS was found to activate
both MAPKAP-K1 and MAPKAP-K2 with a half-life of just
over 30 min. In both cases activation peaked after 1 h and
then declined sharply. However, in the case of MAPKAP-K2,
a second wave of activation occurred after 4 h (Fig. 1). The
activation of MAPKAP-K1 was completely suppressed by PD
98059, while the activation of MAPKAP-K2 was prevented
by SB 203580 (Fig. 1).
Although the experiments in Fig. 1 were performed in the
presence of both LPS and IFNQ in order to achieve maximal
induction of iNOS and CAT-2B, omitting IFNQ did not a¡ect
the activation of MAPKAP-K1 or MAPKAP-K2 up to 1 h,
and IFNQ alone did not activate either protein kinase (data
not shown).
3.2. The MAPK/ERK and SAPK2/p38 pathways are not
rate-limiting for the induction of iNOS in RAW264
macrophages
Consistent with previous results (reviewed in [17]), LPS/
IFNQ induced the appearance of iNOS activity, as judged by
the appearance of nitrite in the medium (Fig. 2A), as well as
the iNOS protein itself (Fig. 2B). Activity (Fig. 2A) and pro-
tein (data not shown) both started to appear after 2 h and
reached a maximal level after about 6 h (Fig. 2A). The LPS-
induced synthesis of iNOS protein (Fig. 2B) or activity (Fig.
2C) was una¡ected by PD 98059 and/or SB 203580 under
conditions where the activation of MAPKAP-K1 or MAP-
KAP-K2 was blocked completely (Fig. 1). Nitrite production
was prevented by either NMMA, a speci¢c inhibitor of nitric
oxide synthetases, or by the protein synthesis inhibitor aniso-
mycin (Fig. 2C).
Similar results were obtained if IFNQ was omitted, except
that the induction of iNOS protein and activity was much
smaller (data not shown). IFNQ alone induced hardly any
nitrite production (open triangle in Fig. 2A).
3.3. The MAPK/ERK and SAPK2/p38 cascades both
contribute to the LPS-induced stimulation of arginine
transport in RAW264 macrophages
The production of nitric oxide is dependent not only on the
presence of iNOS, but also on the availability of the substrate
arginine (see Section 1). We con¢rmed that arginine uptake
was stimulated by LPS/IFNQ with similar kinetics to the in-
duction of iNOS (Fig. 3). A 2.5-fold stimulation was routinely
observed after 8 h (Fig. 3A). Interestingly, and in contrast to
iNOS induction, PD 98059 and SB 203580 both inhibited the
LPS-stimulated uptake of arginine. Either inhibitor added
alone caused a partial inhibition, but there was essentially
complete inhibition when the cells were exposed to both in-
hibitors (Fig. 3B). Similar results were obtained if IFNQ was
omitted, except that the stimulation of arginine uptake was
smaller (not shown). IFNQ alone did not stimulate arginine
uptake signi¢cantly (open triangles in Fig. 3A).
The LPS-stimulated increase in arginine transport was pre-
vented by anisomycin (Fig. 3B), indicating that it resulted
from increased synthesis of an arginine transporter or another
protein required for transporter activity. At least two cationic
amino acid transporters (CAT-1 and CAT-2B) are present in
macrophages. CAT-1 is present in unstimulated cells and its
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Fig. 2. E¡ect of di¡erent inhibitors on the LPS-induced synthesis of iNOS protein and activity in RAW264 macrophages. A: Macrophages
were incubated for the times indicated in the presence (closed circles) or absence (open circles) of LPS (100 ng/ml) plus IFNQ (10 U/ml). Nitrite
accumulation in the medium was then measured as described in Section 2.4. B: Macrophages were incubated for 1 h in the presence or absence
of PD 98059 (50 WM) and/or SB 203580 (10 WM), then stimulated for 6 h in the absence or presence of LPS plus IFNQ in the continued pres-
ence or absence of the inhibitors. Cell lysate (30 Wg protein) was denatured in SDS and electrophoresed on a 10% SDS/polyacrylamide gel.
After transfer to a nitrocellulose membrane, the samples were immunoblotted with anti-iNOS antibody (1.0 Wg/ml). Antibodies were visualised
with the enhanced chemiluminescence detection system (Amersham, Bucks, UK). C: Macrophages were incubated for 1 h in the presence or
absence of PD 98059 (50 WM) and/or SB 203580 (10 WM), or NMMA (250 WM) or anisomycin (10 Wg/ml), then stimulated for 6 h in the ab-
sence or presence of LPS plus IFNQ in the continued presence or absence of the inhibitors. Nitrite accumulation in the medium was then meas-
ured as in A. The results for A and C are presented as the mean þ S.E.M. for two determinations from two separate dishes. Similar results
were obtained in three further experiments.
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level is una¡ected by LPS/IFNQ. In contrast, CAT-2B is ab-
sent in unstimulated cells and only induced in the presence of
LPS/IFNQ (see Section 1). These results are con¢rmed by the
experiment presented in Fig. 4, which also shows that prein-
cubation of macrophages with PD 98059 plus SB 203580 had
no e¡ect on the level of mRNA encoding either CAT-1 or
CAT-2B in the presence or absence of LPS/IFNQ. This result
is considered further in Section 4.
4. Discussion
The production of nitric oxide by macrophages depends on
the availability of arginine, as well as on the activity of iNOS,
but which process is rate-limiting is likely to depend on hor-
monal and nutritional status, as well as on other factors (see
Section 1). In this paper, I have shown that LPS-stimulated
arginine uptake into RAW264 macrophages is prevented by a
combination of the drugs PD 98059 and SB 203580 (Fig. 3C),
and at concentrations where they are thought to be speci¢c
inhibitors of the activation of MAP kinase kinase-1 and the
activity of SAPK2/p38, respectively (reviewed in [14]). This is
consistent with the strong activation of both the ‘classical’
MAP kinase cascade and the SAPK2a/p38 cascade by LPS
(Fig. 1). The 30% reduction in LPS-stimulated nitric oxide
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Fig. 4. E¡ect of PD 98059 and SB 203580 on the transcription of the cationic amino acid transporters CAT-1 and CAT-2B. Macrophages were
incubated for 1 h in the presence or absence of PD 98059 (50 WM) plus SB 203580 (10 WM) then stimulated for 6 h in the absence or presence
of LPS plus IFNQ, and in the continued presence or absence of the inhibitors. Total RNA was extracted from the cells and the level of mRNA
encoding CAT-1 (A) and CAT-2B (B) was determined by using the reverse transcriptase polymerase chain reaction as described in Section 2.6.
Similar results were obtained in two further experiments.
Fig. 3. E¡ect of di¡erent inhibitors on basal and LPS-stimulated arginine uptake in RAW264 macrophages. A: Macrophages were incubated
for the times indicated in the presence (closed circles) or absence (open circles) of LPS (100 ng/ml) plus IFNQ (10 U/ml). Arginine uptake into
the cells was then measured as described Section 2.5. B: Same as A except that the macrophages were incubated for 6 h in the absence or pres-
ence of 10 mM L-lysine. C: Macrophages were incubated for 1 h in the presence of PD 98059 (50 WM) and/or SB 203580 (10 WM), or anisomy-
cin (10 Wg/ml), then stimulated for 6 h in the absence or presence of LPS plus IFNQ and in the continued presence or absence of the inhibitors.
Arginine uptake was then measured as in A. The results in A, B and C are presented as the mean þ S.E.M. for three determinations. Similar re-
sults were obtained in three further experiments.
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accumulation in the presence of both PD 98059 and SB
203580 (Fig. 2C) may re£ect the contribution of arginine
transport to overall nitric oxide production under the condi-
tions studied.
The LPS-induced stimulation of arginine transport was pre-
vented by L-lysine, indicating that the endotoxin was stimulat-
ing a cationic amino acid transporter. Arginine uptake was
also suppressed by anisomycin, indicating a requirement for
de novo protein synthesis (Fig. 3B). Since the mRNA encod-
ing the CAT-2B transporter is induced by LPS, this suggested
that LPS may stimulate arginine transport by inducing the
synthesis of the CAT-2B protein. However, PD 98059 plus
SB 203580 did not a¡ect the LPS-stimulated CAT-2B
mRNA production (Fig. 4). Thus, if CAT-2B synthesis under-
lies the stimulation of arginine uptake, these drugs must be
exerting their e¡ects at a post-transcriptional level. Neverthe-
less, it cannot be excluded that PD 98059 and SB 203580 exert
their e¡ects by another mechanism. For example, they may
suppress the synthesis of another protein that is essential for
CAT-2B activity, or another (as yet unidenti¢ed) CAT iso-
form.
In contrast to arginine transport, the induction of iNOS
was una¡ected by PD 98059 and/or SB 203580 (Fig. 2B),
demonstrating that neither the MAP kinase cascade nor the
SAPK2a/p38 pathway is rate-limiting for this process in
RAW264 macrophages. However, in primary glial cultures,
LPS-induced iNOS synthesis was recently reported to be par-
tially suppressed by either PD 98059 and SB 203580 and al-
most completely prevented in the presence of both compounds
[18]. Thus the protein kinases that are rate-limiting for iNOS
gene transcription appear to vary from cell to cell. The signal
transduction pathway(s) which mediates the LPS-stimulated
induction of iNOS in RAW264 macrophages remains to be
identi¢ed. It could involve one or more of the other MAP
kinase family members whose activity or activation is unaf-
fected by PD 98059 or SB 203580, such as SAPK1/JNK,
SAPK3/ERK6, SAPK4 or SAPK5/ERK5 (reviewed in [14]).
Nevertheless it is clear that, despite the similar kinetics of
LPS-stimulated arginine transport and iNOS induction, di¡er-
ent signal transduction pathways are involved in activating
both processes.
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